Key Highlights

  • Novavax (NASDAQ:NVAX) rose 8.99% to USD 12.00 in the October 9, 2026 session, but no company announcement was found for October 8 or October 9.
  • This is a no-catalyst piece: the latest verified company update is the second quarter 2026 report, which showed Revenue of USD 57 million, a net loss of USD 53 million and raised revenue guidance.
  • Full-year 2026 adjusted total revenue guidance was raised to USD 235 million to USD 275 million, with most expected in the fourth quarter and Sanofi milestones carrying much of the weight.
  • Novavax (NASDAQ:NVAX) held USD 724 million in cash and related balances on June 30, 2026, but its revenue depends on timing events it does not control.

What Is and Is Not Known

Novavax (NASDAQ:NVAX) rose 8.99%, or USD 0.99, to USD 12.00 in the October 9, 2026 session on Volume of 7.623 million shares. A search of company releases and published reports found no announcement dated October 8 or October 9, so there is no company announcement found to name as the catalyst. The stock is volatile, with a reported Beta above 2, and moves of this size can come from sector flows, Vaccine headlines, Options activity or short covering. None of these can be confirmed from the information available. Over 52 weeks the stock is up about 32.17%, so the latest gain adds to a strong run.

Second Quarter Results and Guidance

The most important verified update is the second quarter report released on August 6, 2026. Total revenue was USD 57 million, down 76% from USD 239 million a year earlier, when it included a USD 175 million approval milestone. Product sales were USD 19 million, up 76%, and licensing, royalties and other revenue was USD 38 million. Net loss was USD 53 million, or USD 0.32 per share. Novavax raised its 2026 adjusted total revenue guidance to USD 235 million to USD 275 million from USD 230 million to USD 270 million, and lowered the combined Research and Development and selling expense range to USD 370 million to USD 410 million.

Sanofi Milestones and Risks

Much of the upside rests on Sanofi. The company release describes a USD 125 million milestone payable when a Phase 3 combination COVID-19 and influenza trial starts in the United States or European Union, and a USD 75 million milestone tied to completing Manufacturing technology transfer, expected in mid-2027. Royalties run from the high teens to the low twenties as a share of Sanofi's global net sales of Nuvaxovid. The risk is timing: regulators and Sanofi control when triggers occur, and most 2026 revenue is expected in the fourth quarter. Novavax (NASDAQ:NVAX) ended June with USD 724 million in cash, equivalents, marketable securities and restricted cash, down from USD 751 million at year end.

Where Things Stand

No company announcement found for the October 9, 2026 move in Novavax (NASDAQ:NVAX). The verified backdrop is the August 6 second quarter report, raised 2026 revenue guidance of USD 235 million to USD 275 million and Sanofi milestones. Watch for a Phase 3 combination trial start, regulatory news, Sanofi updates and fourth quarter revenue timing. A gain of 8.99% in one session can reverse quickly.